Kyverna Therapeutics (KYTX) Total Liabilities (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Total Liabilities data on file, last reported at $61.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 67.67% year-over-year to $61.4 million; the trailing twelve-month figure through Mar 2026 stood at $61.4 million (up 67.67% YoY), and the FY2025 full-year result was $61.6 million, up 61.73% from the prior year.
• Total Liabilities for Q1 2026 stood at $61.4 million, roughly flat from $61.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $111.8 million in Q3 2023 and bottomed at $26.0 million in Q4 2023.
• The 4-year median for Total Liabilities is $38.1 million (2024), against an average of $53.1 million.
• The widest annual swing landed in 2024, when Total Liabilities tumbled 69.54%; it then surged 67.67% in 2026.
• A 4-year view of Total Liabilities shows it stood at $26.0 million in 2023, then soared by 46.28% to $38.1 million in 2024, then soared by 61.73% to $61.6 million in 2025, then slipped by 0.17% to $61.4 million in 2026.
• The last three Total Liabilities figures came in at $61.4 million (Q1 2026), $61.6 million (Q4 2025), and $35.2 million (Q3 2025), per Business Quant data.

Peer Comparison